Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 248

Similar articles for PubMed (Select 15096075)

1.

Adherence to conventional and atypical antipsychotics after hospital discharge.

Diaz E, Neuse E, Sullivan MC, Pearsall HR, Woods SW.

J Clin Psychiatry. 2004 Mar;65(3):354-60.

PMID:
15096075
2.

[Cost-effectiveness analysis of schizophrenic patient care settings: impact of an atypical antipsychotic under long-acting injection formulation].

Llorca PM, Miadi-Fargier H, Lançon C, Jasso Mosqueda G, Casadebaig F, Philippe A, Guillon P, Mehnert A, Omnès LF, Chicoye A, Durand-Zaleski I.

Encephale. 2005 Mar-Apr;31(2):235-46. Review. French.

PMID:
15959450
3.

[Antipsychotics in bipolar disorders].

Vacheron-Trystram MN, Braitman A, Cheref S, Auffray L.

Encephale. 2004 Sep-Oct;30(5):417-24. Review. French.

PMID:
15627046
4.
5.

Rehospitalization rates of chronically ill schizophrenic patients discharged on a regimen of risperidone, olanzapine, or conventional antipsychotics.

Rabinowitz J, Lichtenberg P, Kaplan Z, Mark M, Nahon D, Davidson M.

Am J Psychiatry. 2001 Feb;158(2):266-9.

PMID:
11156809
6.

Rates and predictors of adherence with atypical antipsychotic medication: a follow-up study of adolescent inpatients.

Pogge DL, Singer MB, Harvey PD.

J Child Adolesc Psychopharmacol. 2005 Dec;15(6):901-12.

PMID:
16379510
7.

Reducing violence risk in persons with schizophrenia: olanzapine versus risperidone.

Swanson JW, Swartz MS, Elbogen EB, Van Dorn RA.

J Clin Psychiatry. 2004 Dec;65(12):1666-73.

PMID:
15641872
8.

Assessment of strategies for switching patients from olanzapine to risperidone: a randomized, open-label, rater-blinded study.

Ganguli R, Brar JS, Mahmoud R, Berry SA, Pandina GJ.

BMC Med. 2008 Jun 30;6:17. doi: 10.1186/1741-7015-6-17.

9.

Antipsychotic treatment discontinuation in previously untreated patients with schizophrenia: 36-month results from the SOHO study.

Haro JM, Novick D, Suarez D, Roca M.

J Psychiatr Res. 2009 Jan;43(3):265-73. doi: 10.1016/j.jpsychires.2008.06.001. Epub 2008 Jul 21.

PMID:
18644606
10.

Treatment adherence among patients with schizophrenia treated with atypical and typical antipsychotics.

Gianfrancesco FD, Rajagopalan K, Sajatovic M, Wang RH.

Psychiatry Res. 2006 Nov 15;144(2-3):177-89. Epub 2006 Sep 27.

PMID:
17010448
11.

Early clinical experience with risperidone long-acting injection: a prospective, 6-month follow-up of 100 patients.

Taylor DM, Young CL, Mace S, Patel MX.

J Clin Psychiatry. 2004 Aug;65(8):1076-83.

PMID:
15323592
12.

A randomized controlled trial of long-acting injectable risperidone vs continuation on oral atypical antipsychotics for first-episode schizophrenia patients: initial adherence outcome.

Weiden PJ, Schooler NR, Weedon JC, Elmouchtari A, Sunakawa A, Goldfinger SM.

J Clin Psychiatry. 2009 Oct;70(10):1397-406. doi: 10.4088/JCP.09m05284yel.

PMID:
19906343
13.

Time to discontinuation and self-discontinuation of olanzapine and risperidone in patients with schizophrenia in a naturalistic outpatient setting.

Kilzieh N, Todd-Stenberg JA, Kennedy A, Wood AE, Tapp AM.

J Clin Psychopharmacol. 2008 Feb;28(1):74-7. doi: 10.1097/jcp.0b013e3181602cf3.

PMID:
18204345
14.

Response and relapse in patients with schizophrenia treated with olanzapine, risperidone, quetiapine, or haloperidol: 12-month follow-up of the Intercontinental Schizophrenia Outpatient Health Outcomes (IC-SOHO) study.

Dossenbach M, Arango-Dávila C, Silva Ibarra H, Landa E, Aguilar J, Caro O, Leadbetter J, Assunção S.

J Clin Psychiatry. 2005 Aug;66(8):1021-30.

PMID:
16086618
15.

A comparative pilot study of second-generation antipsychotics in children and adolescents with schizophrenia-spectrum disorders.

Jensen JB, Kumra S, Leitten W, Oberstar J, Anjum A, White T, Wozniak J, Lee SS, Schulz SC.

J Child Adolesc Psychopharmacol. 2008 Aug;18(4):317-26. doi: 10.1089/cap.2007.0123.

PMID:
18759641
16.

Cost-effectiveness analysis of switching antipsychotic medication to long-acting injectable risperidone in patients with schizophrenia : a 12- and 24-month follow-up from the e-STAR database in Spain.

Olivares JM, Rodriguez-Martinez A, Burón JA, Alonso-Escolano D, Rodriguez-Morales A; e-STAR Study Group.

Appl Health Econ Health Policy. 2008;6(1):41-53.

PMID:
18774869
17.

Treatment adherence among patients with bipolar or manic disorder taking atypical and typical antipsychotics.

Gianfrancesco FD, Rajagopalan K, Sajatovic M, Wang RH.

J Clin Psychiatry. 2006 Feb;67(2):222-32.

PMID:
16566617
18.

Initiation of atypical antipsychotic agents and health outcomes in patients with schizophrenia.

Ren XS, Lee AF, Huang YH, Hamed A, Herz L, Miller DR, Kazis LE.

J Clin Pharm Ther. 2004 Oct;29(5):471-81.

PMID:
15482392
19.

How effective is it to sequentially switch among Olanzapine, Quetiapine and Risperidone?--A randomized, open-label study of algorithm-based antipsychotic treatment to patients with symptomatic schizophrenia in the real-world clinical setting.

Suzuki T, Uchida H, Watanabe K, Nomura K, Takeuchi H, Tomita M, Tsunoda K, Nio S, Den R, Manki H, Tanabe A, Yagi G, Kashima H.

Psychopharmacology (Berl). 2007 Dec;195(2):285-95. Epub 2007 Aug 14.

PMID:
17701027
20.
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk